US equities |
SPCX $174.53 ▲+2.01% NVDA $242.04 ▲+1.32% MU $1,062.21 ▼-0.16% MRVL $287.70 ▲+6.06% AMD $639.08 ▲+1.16% SNDK $1,680.64 ▼-1.38% TSLA $379.86 ▲+0.30% META $740.07 ▼-0.25%
FinancialContent

Articles published by CN Bio

News headline image
CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium
From CN Bio
Via Business Wire
News headline image
CN Bio Awarded Innovate UK Grant to Reduce Animal Use in Pharmacokinetic Studies
From CN Bio
Via Business Wire
News headline image
CN Bio Launches All-in-one Organ-on-a-chip System, PhysioMimix® Core
From CN Bio
Via Business Wire
News headline image
CN Bio Adds Computational Modeling Capabilities to ADME Services for Enhanced Bioavailability Profiling
From CN Bio
Via Business Wire
News headline image
CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development
From CN Bio
Via Business Wire
News headline image
CN Bio and Pharmaron Establish Long-Term Strategic Partnership to Develop OOC Technologies on a Global R&D Platform
From CN Bio
Via Business Wire
News headline image
CN Bio Launches PhysioMimix DILI Assay Kit: Human 24, for Enhanced Preclinical Toxicology Testing
From CN Bio
Via Business Wire
News headline image
CN Bio Launches PhysioMimix Bioavailability Assay Kit: Human 18
From CN Bio
Via Business Wire
News headline image
CN Bio Raises $21 Million USD in First Close of Series B Investment Round
From CN Bio
Via Business Wire
News headline image
CN Bio and Altis Biosystems Partner to Develop Next-generation Human Gut/Liver in vitro model for Advanced ADME Studies
From CN Bio
Via Business Wire
News headline image
CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822 for Metabolic Liver Disease Treatment Now in Clinical Testing
From CN Bio
Via Business Wire
News headline image
CN Bio Wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for Ongoing Research With the FDA
From CN Bio
Via Business Wire
News headline image
CN Bio Appoints Dr. Samantha Macro as Chief Financial Officer
From CN Bio
Via Business Wire
News headline image
CN Bio Appoints Deepak Singh as Vice President of Sales and Marketing
From CN Bio
Via Business Wire
News headline image
CN Bio Extends Microphysiological System Portfolio With PhysioMimix Single-Organ Higher Throughput System
From CN Bio
Via Business Wire
News headline image
The FDA Further Expands Collaboration With CN Bio to Evaluate the PhysioMimix Multi-Organ Microphysiological System
From CN Bio
Via Business Wire
News headline image
CN Bio appoints Dr Paul Brooks as Chief Executive Officer
From CN Bio
Via Business Wire
News headline image
CN Bio Opens New Laboratory Facilities to Extend Organ-on-a-chip Contract Research Services Capabilities
From CN Bio
Via Business Wire
News headline image
CN Bio Appoints Dr Paul Brooks as Chief Business Officer
From CN Bio
Via Business Wire
News headline image
CN Bio Introduces PhysioMimix NASH ‘in-a-box’ Reagent Kit
From CN Bio
Via Business Wire
News headline image
CN Bio and iiCON Announce COVID-19 Research Collaboration
From CN Bio
Via Business Wire
News headline image
CN Bio Expands Service Offering to Support Oncology Drug Discovery
From CN Bio
Via Business Wire
News headline image
CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
From CN Bio
Via Business Wire
News headline image
CN Bio’s PhysioMimix™ Adopted by King’s College London to Investigate Chronic Liver Disease
From CN Bio
Via Business Wire
News headline image
The FDA Expands Collaboration With CN Bio to Investigate Lung-on-a-chip Model for Inhaled Drug Evaluation Applications
From CN Bio
Via Business Wire